The global pipeline of cell therapies for cancer

  title={The global pipeline of cell therapies for cancer},
  author={Jia Xin Yu and V. M. Hubbard-Lucey and Jun Tang},
  journal={Nature Reviews Drug Discovery},
cell therapies to treat CD19-positive haematological cancers have encouraged substantial R&D efforts with cell therapies in oncology. Indeed, cell therapies now represent the largest number of active agents in development in the immunooncology field overall (Nat. Rev. Drug Discov. 17, Trends in the cell therapy landscape Cancer cell therapy platforms and targets. The global cell therapy pipeline includes 1,011 active agents, 258 more than a year ago. Among the different cell therapy types, the… Expand

Figures and Topics from this paper

Promises and challenges of adoptive T-cell therapies for solid tumours
Key advances have been made in understanding genetic intratumour heterogeneity, and strategies to accurately identify neoantigens, overcome T-cell exhaustion and circumvent tumour immunosuppression after cell-therapy infusion are being developed. Expand
Industrializing engineered autologous T cells as medicines for solid tumours
There are challenges to the broader industrialization of cells as medicines, especially in the treatment of solid tumours, and an industry perspective on the progress achieved by engineered T cell therapies and strategies to industrialize their potential is provided. Expand
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.
The current knowledge of CI in breast cancer is provided, focusing on candidate biomarkers, ongoing clinical trials, limitations, and immediate future perspectives. Expand
Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma.
Current CAR-T therapy targets in the treatment of HCC are summarized, current obstacles and possible solutions in the process are discussed, and potential strategies to improve the efficacy ofCAR-T cells are described for patients with HCC. Expand
[The use of immune checkpoint inhibitors in routine oncology].
  • J. Schardt
  • Medicine
  • Zeitschrift fur Rheumatologie
  • 2020
An overview of the treatment landscape with immune checkpoint inhibitors, especially for solid tumors in oncology, and the understanding of primary and secondary mechanisms of resistance to immune checkpoint inhibitor has just begun to evolve is provided. Expand
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Standardized and modular flow cytometry assays for CAR-T cell clinical research are introduced, which could also be adapted in the future as quality controls during the CAR- T cell manufacturing process. Expand
Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
Data is reviewed on the use of dual targeting with CAR T cells from early phase clinical trials aimed at treating B cell malignancies and multiple myeloma to mitigate immunophenotypic selective pressures. Expand
Clinical development of cell therapies for cancer: The regulators' perspective.
This work recommends early consideration of collaborative networks, early-access schemes, reducing bias in single-arm trials, adaptive trials, clinical end-points supporting risk/benefit and cost/benefit analyses, companion diagnostics, real-world data and common technical issues. Expand
Investigating T Cell Immunity in Cancer: Achievements and Prospects
Mechanisms utilized by tumour cells to reduce their visibility to CD8+ Cytotoxic T lymphocytes (CTL), as well as therapeutic strategies trialled to overcome these tumour-evasion mechanisms are examined. Expand
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
Current clinical outcomes of CART immunotherapy in B‐cell non‐Hodgkin lymphomas are summarized, the most up‐to‐date understanding of mechanisms of relapse are described, and novel strategies to address resistance to CART therapy are discussed. Expand